HighCape Capital Acquisition Corp. II (HCCR)
HighCape Capital Acquisition II is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
We intend to focus on industries that complement our management team’s background in life sciences and life sciences related industries, and to capitalize on the ability of our management team to identify and acquire a business within those industries.
We intend to focus our investment effort broadly across the entire life sciences industry, which encompasses therapeutics, devices, diagnostics, medical information technology and digital health companies.
We were formed by our sponsor, which is an affiliate of HighCape, a life sciences investment firm with a focus on active investing in commercial stage companies.
HighCape typically invests in companies that have FDA cleared products and are at the point of product launch or have already generated revenue for multiple years.
Collectively, this group has been actively involved in initial public offerings and exits totaling in excess of $5 billion.
|Industry||Blank Checks / SPAC|
452 Fifth Avenue, 21st Floor
New York, NY 10018
|Reporting Currency||US Dollars|
|Kevin Rakin||Chief Executive Officer and Chairman of the Board of Directors|
|Matt Zuga||Chief Financial Officer, Chief Operating Officer and Director|
|David Colpman||Director Nominee|
|Antony Loebel, M.D.||Director Nominee|
|Robert Taub||Director Nominee|